Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01466114|
Recruitment Status : Unknown
Verified April 2017 by Rhonda Voskuhl, University of California, Los Angeles.
Recruitment status was: Recruiting
First Posted : November 7, 2011
Last Update Posted : April 20, 2017
|Condition or disease||Intervention/treatment||Phase|
|Relapsing-remitting Multiple Sclerosis Secondary-progressive Multiple Sclerosis Primary-progressive Multiple Sclerosis||Drug: estriol Other: Placebo Drug: Norethindrone Other: Progestin Placebo||Phase 2|
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments for cognitive function in Multiple Sclerosis. Multiple sclerosis relapses are known to be significantly decreased by approximately 80% during late pregnancy. This disease improvement may be due to estriol, an estrogen unique to pregnancy. Estriol blood levels go from undetectable levels prior to pregnancy, increase during pregnancy and reach highest levels during late pregnancy. Further, estrogen treatment has been shown to have favorable effects on cognition in animal models of other neurological diseases. This proposal will establish whether oral treatment with estriol, induces an improvement in cognitive functioning in subjects with multiple sclerosis when used in combination with the major FDA-approved standard treatments for MS, (Betaseron® (or Extavia®), Rebif®, Avonex®, Copaxone®, Gilenya®, Aubagio®, or Tecfidera®).
The combination of standard MS treatment plus estriol pill (8 mg per day) will be compared to standard MS treatment plus placebo in a double-blinded fashion. The duration of treatment will be one year and the primary outcome measure will be cognitive testing processing speed ability.
Secondary outcomes will be improvement in other cognitive tests, brain MRIs, cognitive evoked potentials, as well as relapse rates and disability measures (EDSS, 25 foot walk, 9 hole peg test, low contrast visual acuity, MS Quality of Life, Modified Fatigue Impact Scale, Beck Depression Inventory, Level of Activity using accelerometry). Safety measures (blood tests and gynecologic evaluations) will also be followed. The overall goal of this study will be the development of an oral treatment, estriol, to improve cognitive function in MS.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||64 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: Group A: Estriol
Standard MS Treatment + Estriol
4 capsules of 2 mg (total of 8 mg) PO QD
Other Name: Synapause
Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
Other Name: Progestin
Placebo Comparator: Group B: Placebo
Standard MS Treatment + Placebo
4 capsules PO QD
Other: Progestin Placebo
Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
- Change from baseline in cognitive function assessed by Paced Serial Addition Test (PASAT). [ Time Frame: 1 year ]Processing speed will be assessed by PASAT. Numerical test scores (ranging from 0-60) will be acquired, then percent change for each subject at trial conclusion as compared to baseline will be determined. Whether greater improvement as expressed as percent change occurs in the estriol group as compared to the placebo group will be determined.
- Change from baseline in cognitive function as assessed by cognitive evoked potentials, measured in milliseconds. [ Time Frame: 1 year ]Cognitive evoked potentials will be recorded in msecs for each subject at baseline and conclusion. The percent improvement as conclusion as compared to baseline for each subject will be determined. Group comparisons will reveal whether the percent improvement is greater in the estriol treated group as compared to the placebo treated group.
- Change from baseline in standard MS outcome measures. [ Time Frame: 1 year ]Determine whether the combination treatment has an effect on standard MS outcome measures (relapses, EDSS, 25 foot walk test, 9 hole peg test, low contrast visual acuity, MS Quality of Life, Modified Fatigue Impact Scare, Beck Depression Inventory.
- Determine safety by assessing the number of subjects with adverse events with combination treatment as compared to placebo. [ Time Frame: 1 year ]Determine whether the combination treatment is safe (based on neurologic exams, laboratory tests (Chemistries, CBC), and gynecologic exams (breast and gynecologic exams).
- Change from baseline in cognitive function as assessed by a brief battery of cognitive tests. [ Time Frame: 1 year ]A brief battery of cognitive tests will be administered including: Processing speed: SDMT; Visual memory: 7/24 Spatial Recall Test, Benton Forms F & G; Verbal memory: Buschke Selective Reminding Test, Verbal Paired Associates; Language: Word List Generation. Each subject will be tested at baseline, month 6 and conclusion. Percent change at conclusion as compared to baseline will be determined in each subject. Group comparisons will reveal which cognitive test within the battery had greater improvement in the estriol treated group as compared to the placebo treated group.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01466114
|Contact: Mike Montag, M.S.||(310)206-2176||MMontag@mednet.ucla.edu|
|United States, California|
|University of California Los Angeles||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Mike Montag, M.S. 310-206-2176 MMontag@mednet.ucla.edu|
|Sub-Investigator: Barbara Giesser, MD|
|Sub-Investigator: Callene Momtazee, MD|
|United States, Colorado|
|The University of Colorado Denver||Completed|
|Aurora, Colorado, United States, 80045|
|United States, New Mexico|
|The University of New Mexico||Completed|
|Albuquerque, New Mexico, United States, 87131|
|United States, Pennsylvania|
|The University of Pennsylvania||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Amber Roberts 215-662-4893 email@example.com|
|Principal Investigator: Dina Jacobs, M.D.|
|Principal Investigator:||Rhonda Voskuhl, M.D.||University of California, Los Angeles|